Upstream Bio Phase 2 VIBRANT trial meets primary endpoint for verekitug in CRSwNP

Upstream Bio, Inc.

Placebo-adjusted reduction in nasal polyp score of -1.8 (p<0.0001) at Week 24; key secondary endpoint nasal congestion score reduced -0.8 (p=0.0003).
76% reduction in need for surgery or systemic corticosteroids (p=0.03); no serious adverse events observed.
Verekitug (100 mg every 12 weeks) generally well tolerated; company plans to engage regulators and present at upcoming medical conference.
Additional top-line data for verekitug in severe asthma expected in coming months.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.